hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06266247, orgStudyIdInfo id: 06-2023/16, secondaryIdInfos id: KMU-BAP, type: OTHER, domain: KMU, briefTitle: How Sirtuin Levels Change During Behçet Disease, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-10-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Karamanoğlu Mehmetbey University, class: OTHER, descriptionModule briefSummary: Our primary aim in our study is to evaluate the relationship between the activity, which will be evaluated by clinical and standard phase reactants, and the IL-6 and TNF-α levels, which will be measured in serum, in Behçet\&#39;s patients. Our secondary aim was to evaluate Sirtuin-1 in Behcet\&#39;s patients and compare it with the normal population. Our third aim is to find out whether there is a relationship between these values and organ involvement., conditionsModule conditions: Behçet Disease, conditions: Inflammation, conditions: Vasculitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Take blood samples, outcomesModule primaryOutcomes measure: Our primary aim is to evaluate the relationship between the activity to be evaluated with clinical and standard acute phase reactants and the IL-6 and TNF-α levels to be measured in serum in Behçet's patients., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Karamanoğlu Mehmetbey University, city: Karaman, country: Turkey, geoPoint lat: 37.18111, lon: 33.215, hasResults: False
protocolSection identificationModule nctId: NCT06266195, orgStudyIdInfo id: 5452, briefTitle: Spectroscopic Profiling of Extracellular Vesicles By Resonant Gold Nanostructures in the Infrared, acronym: PROVEIR_1, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-15, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: Extracellular vesicles, due to their ease of extraction and ability to represent the cells from which they originate, have high potential in the field of personalized medicine, especially in the identification of new early bio-markers of cancer, including hepatocellular carcinoma. Nevertheless, the development of high-throughput diagnostic methods in this area is still in its infancy, and the design of new integrated technological solutions is of great interest and topicality. The main hypothesis of this study is that the development of a novel technology integrating resonant gold nanostructures in the mid-infrared can significantly contribute to the development of new approaches for the diagnosis of hepatocellular carcinoma., conditionsModule conditions: Vesicle, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: sierological test, outcomesModule primaryOutcomes measure: primary endpoint, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: FPGemelliIRCCS, status: RECRUITING, city: Roma, state: Lazio, zip: 00168, country: Italy, contacts name: Fabrizio Pizzolante, MD PhD, role: CONTACT, phone: +390630151, email: fabrizio.pizzolante@policlinicogemelli.it, contacts name: Gabriele Ciasca, Professor, role: CONTACT, phone: +390630151, email: gabriele.ciasca@unicatt.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06266156, orgStudyIdInfo id: BMU-HTUNC-01, briefTitle: Evaluation of The Effect of Consecutive Dental Visits on Dental Anxiety of Paediatric Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-08-05, primaryCompletionDateStruct date: 2023-11-03, completionDateStruct date: 2023-12-27, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Burdur Mehmet Akif Ersoy University, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to learn about in effect of consecutive dental visits on dental anxiety of paediatric patients.The main question\[s\]it aims to answer are:* Did the anxiety level of pediatric patients decrease in consecutive treatment sessions?* Were there changes in the physiological parameters related to stress level of pediatric patients in consecutive treatment sessions?Participants will fill out the questionnaire about dental anxiety in each dental treatment sessions before and after dental treatment.Researchers will compare paeditric patients have two caries on mandibular molars to see if changes dental anxiety levels and physiological parameters such as heart rates and oxygen saturations during dental treatments in consecutive dental treatment sessions., conditionsModule conditions: Dental Anxiety, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 240, type: ACTUAL, armsInterventionsModule interventions name: Score of anxiety questionnaire, interventions name: Heart rate, interventions name: Oxygen saturation, outcomesModule primaryOutcomes measure: Determination of sample size., primaryOutcomes measure: Inviting participants to the study., primaryOutcomes measure: Determination of dental anxiety score of participants before dental treatment in first dental session, primaryOutcomes measure: Heart rate measuring in first dental session., primaryOutcomes measure: Oxygen saturation measuring in first dental session., primaryOutcomes measure: Determination of dental anxiety score of participants after dental treatment in first dental session, primaryOutcomes measure: Determination of dental anxiety score of participants before dental treatment in second dental session, primaryOutcomes measure: Heart rate measuring in second dental session., primaryOutcomes measure: Oxygen saturation measuring in second dental session., primaryOutcomes measure: Determination of dental anxiety score of participants after dental treatment in second dental session, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 9 Years, stdAges: CHILD, contactsLocationsModule locations facility: Burdur Mehmet Akif Ersoy University Faculty of Dentistry, city: Burdur, state: Centrum, zip: 15100, country: Turkey, geoPoint lat: 37.72028, lon: 30.29083, hasResults: False
protocolSection identificationModule nctId: NCT06266143, orgStudyIdInfo id: Y101D03, briefTitle: A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-02-08, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Wuhan YZY Biopharma Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The Phase Ib/II study is an open-label, single-arm, multicenter trial designed to assess the efficacy and safety of Y101D in combination with Gemcitabine and Albumin Paclitaxel as first-line systemic treatment for advanced pancreatic cancer patients. The Phase Ib portion of the study aims to evaluate the safety of escalating doses of Y101D in combination with the standard regimen of Gemcitabine and Albumin Paclitaxel and determine the recommended phase 2 dose (RP2D). The Phase II portion of the study aims to evaluate the effectiveness of this combination treatment in a small population of patients., conditionsModule conditions: Advanced Pancreatic Adenocarcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 71, type: ACTUAL, armsInterventionsModule interventions name: Y101D, outcomesModule primaryOutcomes measure: Dose Limiting Toxicities (DLTs), primaryOutcomes measure: RP2D, primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Peak Serum Concentration (Cmax), secondaryOutcomes measure: Trough Serum Concentration (Ctrough), secondaryOutcomes measure: Area under the serum concentration versus time curve (AUC) during one treatment cycle (21 days), secondaryOutcomes measure: The TGF-β concentration in serum, secondaryOutcomes measure: The CA19-9 concentration in serum, secondaryOutcomes measure: The positive rate of Anti-Drug Antibody (ADA) and Neutralizing antibody (Nab), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, city: Wuhan, state: Hubei, zip: 430022, country: China, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06266130, orgStudyIdInfo id: EM-11-050087, briefTitle: Digital Bonding vs. Direct Bonding Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2026-08, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: 3M, class: INDUSTRY, descriptionModule briefSummary: This is a prospective, 2-armed, randomized, multi-site clinical study to demonstrate that digital bonding is a more efficient treatment method than direct placement of brackets., conditionsModule conditions: Orthodontic Brackets, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: There are two groups, treatment group (digital bonding) and control group (direct bonding). Subjects will be enrolled and randomized into treatment or control group at each orthodontic practice., primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: Due to the nature of the devices, Investigator blinding is not feasible for the study., enrollmentInfo count: 178, type: ESTIMATED, armsInterventionsModule interventions name: Treatment Group Digital Bonding Tray, interventions name: Control Group Direct Bonding, outcomesModule primaryOutcomes measure: Prep-and-bonding time, secondaryOutcomes measure: Number of adjustment visits to complete treatment, secondaryOutcomes measure: Overall chair time, eligibilityModule sex: ALL, minimumAge: 12 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06266117, orgStudyIdInfo id: SBF-HMS-GES-03, briefTitle: Pain, Anxiety, and Comfort Levels in Coronary Angiography, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Abant Izzet Baysal University, class: OTHER, descriptionModule briefSummary: The study was designed as a descriptive study. The universe of the study is İzzet Baysal Training and Research Hospital; It consists of patients who underwent coronary angiography in the coronary intensive care unit., conditionsModule conditions: Pain, conditions: Anxiety, conditions: Nursing Caries, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 216, type: ESTIMATED, outcomesModule primaryOutcomes measure: Pain level, primaryOutcomes measure: Anxiety, primaryOutcomes measure: Comfort, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Abant Izzet Baysal University Faculty of Health Science, city: Bolu, state: Merkez, zip: 14100, country: Turkey, geoPoint lat: 40.73583, lon: 31.60611, hasResults: False
protocolSection identificationModule nctId: NCT06266104, orgStudyIdInfo id: Protocol V1.4_04012024, briefTitle: Image Enhanced Endoscopy IBD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-03, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-03-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Royal Perth Hospital, class: OTHER, descriptionModule briefSummary: Dye- spray chromoendoscopy remains the recommended gold standard approach for IBD dysplasia surveillance colonoscopy however recently published European and American guidelines recommend either dye-spray or virtual chromoendoscopy can be used for surveillance. The newer Imaged Enhanced Endoscopy technologies TXI and LCI have not formally been evaluated in IBD surveillance in a randomised controlled trial setting. These modes can easily be applied during colonoscopy and if demonstrated to be effective may save time and eliminate the need for dye-spray chromoendoscopy in the future., conditionsModule conditions: Inflammatory Bowel Diseases, conditions: Dysplasia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 270, type: ESTIMATED, armsInterventionsModule interventions name: Image Enhanced Endoscopy Filters, outcomesModule primaryOutcomes measure: Dysplasia Detection Rate, secondaryOutcomes measure: Withdrawal times, secondaryOutcomes measure: Characterisation of lesions, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Royal Perth Hosptial, status: RECRUITING, city: Perth, state: Western Australia, zip: 6000, country: Australia, contacts name: Sherman Picardo, MBBS, role: CONTACT, phone: 92242244, geoPoint lat: -31.95224, lon: 115.8614, hasResults: False
protocolSection identificationModule nctId: NCT06266091, orgStudyIdInfo id: M70102, briefTitle: Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2021-11-24, primaryCompletionDateStruct date: 2024-03-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Wuhan YZY Biopharma Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: A Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 in treating Patients with Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer combined with Systemic Therapy., conditionsModule conditions: Malignant Ascites, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: M701, interventions name: paracentesis, outcomesModule primaryOutcomes measure: Puncture-free survival, PuFS, secondaryOutcomes measure: objective response rate (ORR) of malignant ascites, secondaryOutcomes measure: Progression-free Survival, PFS, secondaryOutcomes measure: Overall survival, OS, secondaryOutcomes measure: Quality of Life, QoL, secondaryOutcomes measure: Safety profiles, secondaryOutcomes measure: Positive rate of ADA and Nab in serum, secondaryOutcomes measure: The EpCAM expression in ascites, secondaryOutcomes measure: Trough serum concentration (Ctrough), secondaryOutcomes measure: Peak serum concentration (Cmax), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Medical Center of Chinese PLA General Hospital, city: Beijing, state: Beijing, zip: 100141, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06266052, orgStudyIdInfo id: 2019/04, briefTitle: Evaluation of the Effects of Four Different Flap Designs on Tissue Healing in Lower Third Molar Surgery, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-20, primaryCompletionDateStruct date: 2024-03-20, completionDateStruct date: 2024-04-20, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Recep Tayyip Erdogan University, class: OTHER, descriptionModule briefSummary: The aim of this study is to prospectively evaluate the effectiveness of 4 different flap types used during mandibular impacted wisdom teeth surgery on postoperative quality of life, soft tissue and hard tissue healing at the end of the 3rd month., conditionsModule conditions: Soft Tissue Injuries, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Triangular Flap, interventions name: Berwick Flap, interventions name: Saurez Flap, interventions name: Heitz Flap, outcomesModule primaryOutcomes measure: Eudema Amount, primaryOutcomes measure: Pain Level, primaryOutcomes measure: Trismus Level, primaryOutcomes measure: Halitosis Amount, primaryOutcomes measure: bone healing condition, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: RTEU Faculty of Dentistry, city: Rize, country: Turkey, geoPoint lat: 41.02083, lon: 40.52194, hasResults: False
protocolSection identificationModule nctId: NCT06266013, orgStudyIdInfo id: 009, briefTitle: Influence of an Inspiratory Muscle Fatigue Protocol on Older Adults on Respiratory Muscle Strength, Muscle Oxygen Saturation, and Functional Capacity, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2024-02-19, completionDateStruct date: 2024-03-10, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Sierra Varona SL, class: OTHER, collaborators name: Universidad Europea de Madrid, descriptionModule briefSummary: Respiratory muscle training represents an effective method increasingly utilized in both sports and healthcare domains, employing various devices, among which threshold devices are prominent. The aim of this study is to determine the relationship between diaphragmatic fatigue and muscular strength in upper and lower limbs, in both healthy and pathological subjects, as well as the association between such fatigue and other variables, including maximal inspiratory pressure, functionality and muscle tissue oxygen levels.According to our hypothesis, the execution of a protocol inducing diaphragmatic fatigue in older adults could influence muscular strength, cardiorespiratory function, exercise capacity, and muscle tissue oxygenation.In this study, subjects will be divided into three groups: the experimental group, the activation group and the control group.Measurements of variables, such as maximal inspiratory pressure, peripheral muscle tissue oxygen levels, diaphragmatic strength (ultrasound image) and functional capacity, will be conducted., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: the outcome assessor will not know in which group is each participant, and the investigator will receive the data without knowing which data is from which group, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: inspiratory muscle training, outcomesModule primaryOutcomes measure: Muscle oxygen saturation (SmO2), primaryOutcomes measure: Functional mobility, primaryOutcomes measure: Respiratory muscle strength, primaryOutcomes measure: Diaphragmatic thickness and thickening fraction, primaryOutcomes measure: Functional capacity, primaryOutcomes measure: Diaphragm movement curve, eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06266000, orgStudyIdInfo id: PROPAL, briefTitle: Comparison of 2 Extracts of Saw Palmetto Versus Placebo on BPH Symptoms, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: RDC Clinical Pty Ltd, class: INDUSTRY, descriptionModule briefSummary: A randomized, double-blind, placebo-controlled, parallel group study to compare 2 extracts of saw palmetto versus placebo on the symptoms of benign prostate hyperplasia (BPH) in 120 generally healthy participants, 45 - 80 years., conditionsModule conditions: Benign Prostatic Hyperplasia, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Saw palmetto extract 320mg per day, interventions name: Commercial Saw palmetto extract 320mg per day, interventions name: Palm Oil capsule, outcomesModule primaryOutcomes measure: International Prostate Symptom Score (IPSS), primaryOutcomes measure: Daily Urinary Frequency Diary, secondaryOutcomes measure: Brief Sexual Function Inventory (BSFI), secondaryOutcomes measure: International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms Module (ICIQ-MLUTS), secondaryOutcomes measure: Electrolytes (E/LFT) blood test, secondaryOutcomes measure: Liver Function (E/LFT) blood test, secondaryOutcomes measure: Inflammatory marker - JM27, secondaryOutcomes measure: Blood pressure, secondaryOutcomes measure: Pulse rate, secondaryOutcomes measure: Adverse event frequency, secondaryOutcomes measure: Adverse event severity, secondaryOutcomes measure: Discontinuation due to adverse events, eligibilityModule sex: MALE, minimumAge: 45 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: RDC Clinical Pty Ltd, status: RECRUITING, city: Brisbane, state: Queensland, zip: 4006, country: Australia, contacts name: Amanda Rao, PhD, role: CONTACT, phone: +61 414 488 559, email: amanda@rdcglobal.com.au, contacts name: David Briskey, PhD, role: CONTACT, phone: +61 421 784 077, email: david@rdcglobal.com.au, geoPoint lat: -27.46794, lon: 153.02809, hasResults: False